Unknown

Dataset Information

0

The PAR2 inhibitor I-287 selectively targets G?q and G?12/13 signaling and has anti-inflammatory effects.

ABSTRACT: Protease-activated receptor-2 (PAR2) is involved in inflammatory responses and pain, therefore representing a promising therapeutic target for the treatment of immune-mediated inflammatory diseases. However, as for other GPCRs, PAR2 can activate multiple signaling pathways and those involved in inflammatory responses remain poorly defined. Here, we describe a new selective and potent PAR2 inhibitor (I-287) that shows functional selectivity by acting as a negative allosteric regulator on G?q and G?12/13 activity and their downstream effectors, while having no effect on Gi/o signaling and ?arrestin2 engagement. Such selective inhibition of only a subset of the pathways engaged by PAR2 was found to be sufficient to block inflammation in vivo. In addition to unraveling the PAR2 signaling pathways involved in the pro-inflammatory response, our study opens the path toward the development of new functionally selective drugs with reduced liabilities that could arise from blocking all the signaling activities controlled by the receptor.

SUBMITTER: Avet C 

PROVIDER: S-EPMC7695697 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The PAR2 inhibitor I-287 selectively targets Gα<sub>q</sub> and Gα<sub>12/13</sub> signaling and has anti-inflammatory effects.

Avet Charlotte C   Sturino Claudio C   Grastilleur Sébastien S   Gouill Christian Le CL   Semache Meriem M   Gross Florence F   Gendron Louis L   Bennani Youssef Y   Mancini Joseph A JA   Sayegh Camil E CE   Bouvier Michel M  

Communications biology 20201127 1

Protease-activated receptor-2 (PAR2) is involved in inflammatory responses and pain, therefore representing a promising therapeutic target for the treatment of immune-mediated inflammatory diseases. However, as for other GPCRs, PAR2 can activate multiple signaling pathways and those involved in inflammatory responses remain poorly defined. Here, we describe a new selective and potent PAR2 inhibitor (I-287) that shows functional selectivity by acting as a negative allosteric regulator on Gα<sub>q  ...[more]

Similar Datasets

Unknown Receptor selectivity between the G proteins Gα<sub>12</sub> and Gα<sub>13</sub> is defined by a single leucine-to-isoleucine variation.
| S-EPMC6436656 | biostudies-literature
Unknown Targeting Gα<sub>13</sub>-integrin interaction ameliorates systemic inflammation.
| S-EPMC8159967 | biostudies-literature
Unknown Amphetamines signal through intracellular TAAR1 receptors coupled to Gα<sub>13</sub> and Gα<sub>S</sub> in discrete subcellular domains.
| S-EPMC7038576 | biostudies-literature
Unknown Naturally occurring hotspot cancer mutations in Gα<sub>13</sub> promote oncogenic signaling.
| S-EPMC7864081 | biostudies-literature
Unknown An ATX-LPA<sub>6</sub>-Gα<sub>13</sub>-ROCK axis shapes and maintains caudal vein plexus in zebrafish.
| S-EPMC8564058 | biostudies-literature
Unknown Potentiation of receptor responses induced by prolonged binding of Gα<sub>13</sub> and leukemia-associated RhoGEF.
| S-EPMC5503709 | biostudies-literature
Unknown The role of Gα<sub>q</sub>/Gα<sub>11</sub> signaling in intestinal epithelial cells.
| S-EPMC5789759 | biostudies-literature
Unknown Interaction kinetics between p115-RhoGEF and Gα<sub>13</sub> are determined by unique molecular interactions affecting agonist sensitivity.
| S-EPMC9700851 | biostudies-literature
Unknown A small molecule inhibitor of Rheb selectively targets mTORC1 signaling.
| S-EPMC5803267 | biostudies-literature
Unknown Regulation of neurite morphogenesis by interaction between R7 regulator of G protein signaling complexes and G protein subunit Gα<sub>13</sub>.
| S-EPMC5473243 | biostudies-literature